mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models
Jiangdong Qiu, Mengyu Feng, Gang Yang, Zhe Cao, Yueze Liu, Lei You, Taiping Zhang
Topics & Concepts
GemcitabineTumor microenvironmentPancreatic cancerCancer researchImmune systemBlockadeImmune checkpointPI3K/AKT/mTOR pathwayCancerReprogrammingMedicineAntibodyBiologyImmunotherapyReceptorImmunologySignal transductionInternal medicineCellCell biologyGeneticsPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersPI3K/AKT/mTOR signaling in cancer